100 related articles for article (PubMed ID: 14655318)
1. Opportunities and Challenges in Drug Development for Pediatric Cancers.
Laetsch TW; DuBois SG; Bender JG; Macy ME; Moreno L
Cancer Discov; 2021 Mar; 11(3):545-559. PubMed ID: 33277309
[TBL] [Abstract][Full Text] [Related]
2. Rescuing Drugs That are Discontinued in Adult Oncology Development for the Benefit of Children and Adolescents With Cancer - An ACCELERATE Multistakeholder Consensus.
de Rojas T; Chiodin D; Pearson ADJ; Heenen D; Adamson P; Caron H; Vassal G
Clin Pharmacol Ther; 2024 Jan; 115(1):36-41. PubMed ID: 37885401
[TBL] [Abstract][Full Text] [Related]
3. Joint recommendations on cost calculation and estimation in paediatric clinical trials.
Ahne G; Nagel J; Franz AR; Neubert A; Schachtrup K; Helms S; Klammt S; Schwab M
Ger Med Sci; 2024; 22():Doc04. PubMed ID: 38774559
[TBL] [Abstract][Full Text] [Related]
4. The Current Status of European and National Financial Sources for Clinical Research and Their Impact on Paediatric Non-commercial Clinical Trials: A Case Study of the Czech Republic.
Horavova L; Nebeska K; Souckova L; Demlova R; Babula P
Ther Innov Regul Sci; 2020 Nov; 54(6):1461-1472. PubMed ID: 32504401
[TBL] [Abstract][Full Text] [Related]
5. Factors Associated with Inclusion of Japan in Phase I Multiregional Clinical Trials in Oncology.
Maki A; Narukawa M
Ther Innov Regul Sci; 2024 Jul; 58(4):766-772. PubMed ID: 38652349
[TBL] [Abstract][Full Text] [Related]
6. Pediatric Cancer Drug Development: Leveraging Insights in Cancer Biology and the Evolving Regulatory Landscape to Address Challenges and Guide Further Progress.
Charlab R; Leong R; Shord SS; Reaman GH
Cold Spring Harb Perspect Med; 2024 Apr; 14(4):. PubMed ID: 38467448
[TBL] [Abstract][Full Text] [Related]
7. Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE.
Gaspar N; Marshall LV; Binner D; Herold R; Rousseau R; Blanc P; Capdeville R; Carleer J; Copland C; Kerloeguen Y; Norga K; Pacaud L; Sevaux MA; Spadoni C; Sterba J; Ligas F; Taube T; Uttenreuther-Fischer M; Chioato S; O'Connell MA; Geoerger B; Blay JY; Soria JC; Kaye S; Wulff B; Brugières L; Vassal G; Pearson ADJ;
Ann Oncol; 2018 Mar; 29(3):766-771. PubMed ID: 29351570
[No Abstract] [Full Text] [Related]
8. Conducting Drug Treatment Trials in Children: Opportunities and Challenges.
Erceg D; Jakirović M; Prgomet L; Madunić M; Turkalj M
Pharmaceut Med; 2024 May; 38(3):179-204. PubMed ID: 38730200
[TBL] [Abstract][Full Text] [Related]
9. CNS Anticancer Drug Discovery and Development: 2016 conference insights.
Levin VA; Abrey LE; Heffron TP; Tonge PJ; Dar AC; Weiss WA; Gallo JM
CNS Oncol; 2017 Jul; 6(3):167-177. PubMed ID: 28718326
[No Abstract] [Full Text] [Related]
10. Preclinical Data Extrapolation to Clinical Reality: A Translational Approach.
Varshney P; Chandra P
Curr Drug Discov Technol; 2024 Apr; ():. PubMed ID: 38676496
[TBL] [Abstract][Full Text] [Related]
11. Literature Review on Health Emigration in Rare Diseases-A Machine Learning Perspective.
Skweres-Kuchta M; Czerska I; Szaruga E
Int J Environ Res Public Health; 2023 Jan; 20(3):. PubMed ID: 36767849
[TBL] [Abstract][Full Text] [Related]
12. Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion Recommendations.
Barry E; Walsh JA; Weinrich SL; Beaupre D; Blasi E; Arenson DR; Jacobs IA
Paediatr Drugs; 2021 Jul; 23(4):381-394. PubMed ID: 34173206
[TBL] [Abstract][Full Text] [Related]
13. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
14. Commentary on "European collaboration in trials of new agents for children with cancer" by Ablett et al.
Smith MA; Anderson BD
Eur J Cancer; 2004 Aug; 40(12):1893-5. PubMed ID: 15288292
[TBL] [Abstract][Full Text] [Related]
15. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
[TBL] [Abstract][Full Text] [Related]
16. Clinical trials in paediatric oncology. Recommendations for the development of new anticancer agents.
Vassal G; Méry-Mignard D; Caulin C
Therapie; 2003; 58(3):229-46. PubMed ID: 14655318
[TBL] [Abstract][Full Text] [Related]
17. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
